Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Vivo Capital Viii, Llc sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $0.96, for a total value of $14,400.00. Following the sale, the insider now owns 143,571 shares in the company, valued at approximately $137,828.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Vivo Capital Viii, Llc also recently made the following trade(s):
- On Monday, November 20th, Vivo Capital Viii, Llc sold 54,700 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $50,324.00.
Bolt Biotherapeutics Trading Down 3.2 %
Shares of NASDAQ BOLT traded down $0.03 during mid-day trading on Monday, hitting $0.91. The stock had a trading volume of 184,152 shares, compared to its average volume of 165,264. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.42 and a current ratio of 6.69. Bolt Biotherapeutics, Inc. has a 1 year low of $0.86 and a 1 year high of $2.03. The firm has a market cap of $34.73 million, a P/E ratio of -0.48 and a beta of 0.83. The business has a 50 day moving average price of $1.01 and a two-hundred day moving average price of $1.28.
Hedge Funds Weigh In On Bolt Biotherapeutics
Analysts Set New Price Targets
A number of equities analysts recently commented on BOLT shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, August 3rd. Stifel Nicolaus decreased their target price on shares of Bolt Biotherapeutics from $7.00 to $6.00 in a research note on Tuesday, August 8th.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
- Five stocks we like better than Bolt Biotherapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- The most upgraded stocks in November have two things in common
- How to Invest in the Best Canadian Stocks
- Monday.com rocked earnings like it’s the weekend
- How to Effectively Use the MarketBeat Ratings Screener
- Plan to own one retailer? Make it this one
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.